19 results on '"Bobyk L"'
Search Results
2. RENEB Inter-Laboratory Comparison 2021: Inter-Assay Comparison of Eight Dosimetry Assays
- Author
-
Port, M., primary, Barquinero, J-F., additional, Endesfelder, D., additional, Moquet, J., additional, Oestreicher, U., additional, Terzoudi, G., additional, Trompier, F., additional, Vral, A., additional, Abe, Y., additional, Ainsbury, L., additional, Alkebsi, L, additional, Amundson, S.A., additional, Badie, C., additional, Baeyens, A., additional, Balajee, A.S., additional, Balázs, K., additional, Barnard, S., additional, Bassinet, C., additional, Beaton-Green, L.A., additional, Beinke, C., additional, Bobyk, L., additional, Brochard, P., additional, Brzoska, K., additional, Bucher, M., additional, Ciesielski, B., additional, Cuceu, C., additional, Discher, M., additional, D,Oca, M.C., additional, Domínguez, I., additional, Doucha-Senf, S., additional, Dumitrescu, A., additional, Duy, P.N., additional, Finot, F., additional, Garty, G., additional, Ghandhi, S.A., additional, Gregoire, E., additional, Goh, V.S.T., additional, Güçlü, I., additional, Hadjiiska, L., additional, Hargitai, R., additional, Hristova, R., additional, Ishii, K., additional, Kis, E., additional, Juniewicz, M., additional, Kriehuber, R., additional, Lacombe, J., additional, Lee, Y., additional, Lopez Riego, M., additional, Lumniczky, K., additional, Mai, T.T., additional, Maltar-Strmečki, N., additional, Marrale, M., additional, Martinez, J.S., additional, Marciniak, A., additional, Maznyk, N., additional, McKeever, S.W.S., additional, Meher, P.K., additional, Milanova, M., additional, Miura, T., additional, Monteiro Gil, O., additional, Montoro, A., additional, Moreno Domene, M., additional, Mrozik, A., additional, Nakayama, R., additional, O'Brien, G., additional, Oskamp, D., additional, Ostheim, P., additional, Pajic, J., additional, Pastor, N., additional, Patrono, C., additional, Pujol-Canadell, M., additional, Prieto Rodriguez, M.J., additional, Repin, M., additional, Romanyukha, A., additional, Rößler, U., additional, Sabatier, L., additional, Sakai, A., additional, Scherthan, H., additional, Schüle, S., additional, Seong, K.M., additional, Sevriukova, O., additional, Sholom, S., additional, Sommer, S., additional, Suto, Y., additional, Sypko, T., additional, Szatmári, T., additional, Takahashi-Sugai, M., additional, Takebayashi, K., additional, Testa, A., additional, Testard, I., additional, Tichy, A.ii A., additional, Triantopoulou, S., additional, Tsuyama, N., additional, Unverricht-Yeboah, M., additional, Valente, M., additional, Van Hoey, O., additional, Wilkins, R.C., additional, Wojcik, A., additional, Wojewodzka, M., additional, Younghyun, Lee, additional, Zafiropoulos, D., additional, and Abend, M., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Nanomaterial genotoxicity: The case of silver nanoparticles
- Author
-
Bobyk, L., Tarantini, A., Béal, D., Veronesi, G., Jouneau, Pierre-Henri, Motellier, S., Sauvaigo, S., Douki, Thierry, Carrière, M., Douki, Thierry, Chimie Interface Biologie pour l’Environnement, la Santé et la Toxicologie (CIBEST ), SYstèmes Moléculaires et nanoMatériaux pour l’Energie et la Santé (SYMMES), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut Nanosciences et Cryogénie (INAC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire d'Etude des Matériaux par Microscopie Avancée (LEMMA ), Modélisation et Exploration des Matériaux (MEM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Département des Technologies des NanoMatériaux (DTNM), Laboratoire d'Innovation pour les Technologies des Energies Nouvelles et les nanomatériaux (LITEN), Institut National de L'Energie Solaire (INES), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Institut National de L'Energie Solaire (INES), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie du CNRS (INC)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de L'Energie Solaire (INES), and Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
- Subjects
[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM] ,[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2017
4. Radiation therapy using synchrotron radiation: Preclinical studies toward clinical trials
- Author
-
Adam, J, Balosso, J, Bobyk, L, Charvet, A, Deman, P, Edouard, M, Elleaume, H, Estève, F, Le Bas, J, Rousseau, J, Serduc, R, Vautrin, M, Chabrol, T, Depaulis, A, Pouyatos, B, Baruchel, J, Berkvens, P, Berruyer, G, Bouchet, A, Bräuer-Krisch, E, Bravin, A, Brochard, T, Dalléry, D, Le Duc, G, Nemoz, C, Martínez-Rovira, I, Prezado, Y, Renier, M, Requardt, H, Benkebil, M, Laissue, J, Adam J. F., Balosso J., Bobyk L., Charvet A.M., Deman P., Edouard M., Elleaume H., Estève F., Le Bas J.F., Rousseau J., Serduc R., Vautrin M., Chabrol T., Depaulis A., Pouyatos B., Baruchel J., Berkvens P., Berruyer G., Bouchet A., Bräuer-Krisch E., Bravin A, Brochard T., Dalléry D., Le Duc G., Nemoz C., Martínez-Rovira I., Prezado Y., Renier M., Requardt H., Benkebil M., Laissue J., Adam, J, Balosso, J, Bobyk, L, Charvet, A, Deman, P, Edouard, M, Elleaume, H, Estève, F, Le Bas, J, Rousseau, J, Serduc, R, Vautrin, M, Chabrol, T, Depaulis, A, Pouyatos, B, Baruchel, J, Berkvens, P, Berruyer, G, Bouchet, A, Bräuer-Krisch, E, Bravin, A, Brochard, T, Dalléry, D, Le Duc, G, Nemoz, C, Martínez-Rovira, I, Prezado, Y, Renier, M, Requardt, H, Benkebil, M, Laissue, J, Adam J. F., Balosso J., Bobyk L., Charvet A.M., Deman P., Edouard M., Elleaume H., Estève F., Le Bas J.F., Rousseau J., Serduc R., Vautrin M., Chabrol T., Depaulis A., Pouyatos B., Baruchel J., Berkvens P., Berruyer G., Bouchet A., Bräuer-Krisch E., Bravin A, Brochard T., Dalléry D., Le Duc G., Nemoz C., Martínez-Rovira I., Prezado Y., Renier M., Requardt H., Benkebil M., and Laissue J.
- Published
- 2011
5. 159: ²¹²Pb-labeled mAbs targeting CEA or HER2 during α-RIT of small peritoneal carcinomatosis – Dose effect relationship?
- Author
-
Pouget, J.-P., primary, Pichard, A., additional, Boudousq, V., additional, Bobyk, L., additional, Ladjohounlou, R., additional, Paillas, S., additional, Le Blay, M., additional, Busson, M., additional, Lozza, C., additional, Maquaire, P., additional, Torgue, J., additional, and Navarro-Teulon, I., additional
- Published
- 2014
- Full Text
- View/download PDF
6. Heavy-atom enhanced synchrotron stereotactic radiotherapy of brain tumors: from DNA to preclinical studies
- Author
-
Bobyk, L., primary, Rousseau, J., additional, Elleaume, H., additional, and Ravanat, J.-L., additional
- Published
- 2008
- Full Text
- View/download PDF
7. Intracerebral delivery of Carboplatin in combination with either 6 MV Photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat glioma
- Author
-
Bobyk Laure, Edouard Magali, Deman Pierre, Rousseau Julia, Adam Jean-François, Ravanat Jean-Luc, Estève François, Balosso Jacques, Barth Rolf F, and Elleaume Hélène
- Subjects
F98 rat glioma ,Carboplatin ,Osmotic pumps ,Intracerebral delivery ,Radiotherapy with 6 MV photons or synchrotron X-rays ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The purpose of the present study was to compare side-by-side the therapeutic efficacy of a 6-day infusion of carboplatin, followed by X-irradiation with either 6 MV photons or synchrotron X-rays, tuned above the K-edge of Pt, for treatment of F98 glioma bearing rats. Methods Carboplatin was administered intracerebrally (i.c.) to F98 glioma bearing rats over 6 days using AlzetTM osmotic pumps starting 7 days after tumor implantation. Radiotherapy was delivered in a single 15 Gy fraction on day 14 using a conventional 6 MV linear accelerator (LINAC) or 78.8 keV synchrotron X-rays. Results Untreated control animals had a median survival time (MeST) of 33 days. Animals that received either carboplatin alone or irradiation alone with either 78.8 keV or 6 MV had a MeSTs 38 and 33 days, respectively. Animals that received carboplatin in combination with X-irradiation had a MeST of > 180 days with a 55% cure rate, irrespective of whether they were irradiated with either 78.8 KeV synchrotron X-rays or 6MV photons. Conclusions These studies have conclusively demonstrated the equivalency of i.c. delivery of carboplatin in combination with X-irradiation with either 6 MV photons or synchrotron X-rays.
- Published
- 2012
- Full Text
- View/download PDF
8. Radiation Therapy Using Synchrotron Radiation: Preclinical Studies Toward Clinical Trials
- Author
-
I. Martínez-Rovira, Laure Bobyk, Jean-François Le Bas, Pierre Deman, P. Berkvens, Anne-Marie Charvet, Alberto Bravin, Géraldine Le Duc, Thierry Brochard, François Estève, Tanguy Chabrol, Audrey Bouchet, Jean A. Laissue, G. Berruyer, Jean-François Adam, Julia Rousseau, Yolanda Prezado, Antoine Depaulis, José Baruchel, Michel Renier, Mehdi Benkebil, Jacques Balosso, Raphaël Serduc, Benoît Pouyatos, Herwig Requardt, M. Edouard, M. Vautrin, Elke Bräuer-Krisch, Christian Nemoz, Hélène Elleaume, Dominique Dallery, INSERM U836, équipe 6, Rayonnement synchrotron et recherche médicale, Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Biomedical Beamline (ID17), European Synchrotron Radiation Facility (ESRF)-European Synchrotron Radiation Facility (ESRF), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biomedical Beamline (ID17), European Synchrotron Radiation Facility (ESRF), High-resolution Diffraction Topography Beamline (ID19), INSERM U836, équipe 9, Dynamique des réseaux synchrones épileptiques, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de techniques énergétiques, Universitat Politècnica de Catalunya [Barcelona] (UPC), DOSIsoft, Oncology - Pathology - Anatomy, Institute of Pathology-University of Bern, Serduc, Raphael, Adam, J, Balosso, J, Bobyk, L, Charvet, A, Deman, P, Edouard, M, Elleaume, H, Estève, F, Le Bas, J, Rousseau, J, Serduc, R, Vautrin, M, Chabrol, T, Depaulis, A, Pouyatos, B, Baruchel, J, Berkvens, P, Berruyer, G, Bouchet, A, Bräuer-Krisch, E, Bravin, A, Brochard, T, Dalléry, D, Le Duc, G, Nemoz, C, Martínez-Rovira, I, Prezado, Y, Renier, M, Requardt, H, Benkebil, M, and Laissue, J
- Subjects
Nuclear and High Energy Physics ,medicine.medical_specialty ,medicine.medical_treatment ,FIS/07 - FISICA APPLICATA (A BENI CULTURALI, AMBIENTALI, BIOLOGIA E MEDICINA) ,Synchrotron radiation ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine ,030218 nuclear medicine & medical imaging ,[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine ,03 medical and health sciences ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Medicine ,Radiation therapy, synchrotron radiation ,Medical physics ,Chemotherapy ,Temozolomide ,business.industry ,Photon irradiation ,Atomic and Molecular Physics, and Optics ,3. Good health ,Radiation therapy ,Clinical trial ,Chemotherapy Drugs ,030220 oncology & carcinogenesis ,business ,medicine.drug - Abstract
International audience; After decades of intensive research, high-grade gliomas are still resistant to therapies, including surgery, chemotherapy, and radiotherapy or a combination thereof. The most important advance in the treatment of these tumors has been the introduction of a new chemotherapy drug called temozolomide, in combination with external beam photon irradiation [1]. One of the goals of the association of the CHU/UJF/ INSERM and ESRF teams has been to develop research on synchrotron radiotherapy up to clinics.
- Published
- 2011
9. Validation of genes for H-ARS severity prediction in leukemia patients - interspecies comparison, challenges, and promises.
- Author
-
Schwanke D, Valente M, Ostheim P, Schüle S, Bobyk L, Drouet M, Riccobono D, Magné N, Daguenet E, Stewart SJ, Muhtadi R, Port M, and Abend M
- Subjects
- Humans, Animals, Whole-Body Irradiation, Blood Cell Count, Papio genetics, RNA, Leukemia, Myeloid, Acute genetics
- Abstract
Purpose: In a previous baboon-study, a total of 29 genes were identified for clinical outcome prediction of the hematologic, acute, radiation, syndrome (H-ARS) severity. Among them, four genes ( FDXR, DDB2, POU2AF1, WNT3) appeared promising and were validated in five leukemia patients. Within this study, we sought further in-vivo validation in a larger number of whole-body irradiated patients., Material and Methods: Peripheral blood was drawn from 10 leukemia patients before and up to 3 days during a fractionated (2 Gy/day) total-body irradiation (TBI) with 2-12Gy. After RNA-isolation, gene expression (GE) was evaluated on 31 genes widely used in biodosimetry and H-ARS prediction employing qRT-PCR. A customized low-density-array (LDA) allowed simultanously analyzing all genes, the 96-well format further examined the four most promising genes. Fold-changes (FC) in GE relative to pre-irradiation were calculated., Results: Five patients suffering from acute-lymphoblastic-leukemia (ALL) respectively non-Hodgkin-lymphoma (NHL) revealed sufficient RNA-amounts and corresponding lymphocyte and neutrophile counts for running qRT-PCR, while acute-myeloid-leukemia (AML) and one myelofibrosis patient could not supply enough RNA. Generally, 1-2µg total RNA was isolated, whereas up to 10-fold differences in RNA-quantities (associated suppressed GE-changes) were identified among pre-exposure and exposure samples. From 31 genes, 23 were expressed in at least one of the pre-exposure samples. Relative to pre-exposure, the number of expressed genes could halve at 48 and 72h after irradiation. Using the LDA, 13 genes were validated in human samples. The four most promising genes (vid. sup.) were either undetermined or too close to pre-exposure. However, they were measured using the more sensitive 96-well format, except WNT3, which wasn´t detectable. As in previous studies, an opposite regulation in GE for FDXR in leukemia patients (up-regulated) relative to baboons (down-regulated) was reconfirmed. Radiation-induced GE-changes of DDB2 (up-regulated) and POU2AF1 (down-regulated) behaved similarly in both species. Hence, 16 out of 23 genes of two species showed GE-changes in the same direction, and up-regulated FDXR as in human studies were revalidated., Conclusion: Identified genes for H-ARS severity prediction, previously detected in baboons, were validated in ALL but not in AML patients. Limitations related to leukemia type, associated reduced RNA amounts, suppressed GE changes, and methodological challenges must be considered as factors negatively affecting the total number of validated genes. Based on that, we propose additional controls including blood cell counts and preferably fluorescence-based RNA quantity measurements for selecting promising samples and using a more sensitive 96-well format for candidate genes with low baseline copy numbers.
- Published
- 2024
- Full Text
- View/download PDF
10. Differential Recruitment of DNA Repair Proteins KU70/80 and RAD51 upon Microbeam Irradiation with α-Particles.
- Author
-
Bobyk L, Vianna F, Martinez JS, Gruel G, Benderitter M, and Baldeyron C
- Abstract
In addition to representing a significant part of the natural background radiation exposure, α-particles are thought to be a powerful tool for targeted radiotherapy treatments. Understanding the molecular mechanisms of recognition, signaling, and repair of α-particle-induced DNA damage is not only important in assessing the risk associated with human exposure, but can also potentially help in identifying ways of improving the efficacy of radiation treatment. α-particles (He
2+ ions), as well as other types of ionizing radiation, and can cause a wide variety of DNA lesions, including DNA double-strand breaks (DSBs). In mammalian cells, DNA DSBs can be repaired by two major pathways: non-homologous end-joining (NHEJ) and homologous recombination (HR). Here, we investigated their dynamics in mouse NIH-3T3 cells through the recruitment of key proteins, such as the KU heterodimer for NHEJ and RAD51 for HR upon localized α-particle irradiation. To deliver α-particles, we used the MIRCOM microbeam, which allows targeting of subnuclear structures with submicron accuracy. Using mouse NIH-3T3 cells, we found that the KU heterodimer is recruited much earlier at DNA damage sites marked by H2AX phosphorylation than RAD51. We also observed that the difference in the response of the KU complex and RAD51 is not only in terms of time, but also in function of the chromatin nature. The use of a microbeam such as MIRCOM, represents a powerful tool to study more precisely the cellular response to ionizing irradiation in a spatiotemporal fashion at the molecular level.- Published
- 2022
- Full Text
- View/download PDF
11. Safe-by-design strategies for lowering the genotoxicity and pulmonary inflammation of multiwalled carbon nanotubes: Reduction of length and the introduction of COOH groups.
- Author
-
Hadrup N, Knudsen KB, Carriere M, Mayne-L'Hermite M, Bobyk L, Allard S, Miserque F, Pibaleau B, Pinault M, Wallin H, and Vogel U
- Subjects
- A549 Cells, Animals, Bronchoalveolar Lavage Fluid chemistry, Bronchoalveolar Lavage Fluid cytology, Comet Assay, DNA Damage, Drug Design, Female, Humans, Inflammation chemically induced, Inflammation immunology, Lung immunology, Mice, Inbred C57BL, Micronucleus Tests, Mutagens chemistry, Nanotubes, Carbon chemistry, Neutrophils drug effects, Neutrophils immunology, Mice, Lung drug effects, Mutagens toxicity, Nanotubes, Carbon toxicity
- Abstract
Potentially, the toxicity of multiwalled carbon nanotubes (MWCNTs) can be reduced in a safe-by-design strategy. We investigated if genotoxicity and pulmonary inflammation of MWCNTs from the same batch were lowered by a) reducing length and b) introducing COOH-groups into the structure. Mice were administered: 1) long and pristine MWCNT (CNT-long) (3.9 μm); 2) short and pristine CNT (CNT-short) (1 μm); 3) CNT modified with high ratio COOH-groups (CNT-COOH-high); 4) CNT modified with low ratio COOH-groups (CNT-COOH-low). MWCNTs were dosed by intratracheal instillation at 18 or 54 μg/mouse (∼0.9 and 2.7 mg/kg bw). Neutrophils numbers were highest after CNT-long exposure, and both shortening the MWCNT and addition of COOH-groups lowered pulmonary inflammation (day 1 and 28). Likewise, CNT-long induced genotoxicity, which was absent with CNT-short and after introduction of COOH groups. In conclusion, genotoxicity and pulmonary inflammation of MWCNTs were lowered, but not eliminated, by shortening the fibres or introducing COOH-groups., (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
12. RENEB/EURADOS field exercise 2019: robust dose estimation under outdoor conditions based on the dicentric chromosome assay.
- Author
-
Endesfelder D, Oestreicher U, Kulka U, Ainsbury EA, Moquet J, Barnard S, Gregoire E, Martinez JS, Trompier F, Ristic Y, Woda C, Waldner L, Beinke C, Vral A, Barquinero JF, Hernandez A, Sommer S, Lumniczky K, Hargitai R, Montoro A, Milic M, Monteiro Gil O, Valente M, Bobyk L, Sevriukova O, Sabatier L, Prieto MJ, Moreno Domene M, Testa A, Patrono C, Terzoudi G, Triantopoulou S, Histova R, and Wojcik A
- Subjects
- Humans, Phantoms, Imaging, Radiometry methods, Chromosome Aberrations radiation effects, Radiation Dosage
- Abstract
Purpose: Biological and/or physical assays for retrospective dosimetry are valuable tools to recover the exposure situation and to aid medical decision making. To further validate and improve such biological and physical assays, in 2019, EURADOS Working Group 10 and RENEB performed a field exercise in Lund, Sweden, to simulate various real-life exposure scenarios., Materials and Methods: For the dicentric chromosome assay (DCA), blood tubes were located at anthropomorphic phantoms positioned in different geometries and were irradiated with a 1.36 TBq
192 Ir-source. For each exposure condition, dose estimates were provided by at least one laboratory and for four conditions by 17 participating RENEB laboratories. Three radio-photoluminescence glass dosimeters were placed at each tube to assess reference doses., Results: The DCA results were homogeneous between participants and matched well with the reference doses (≥95% of estimates within ±0.5 Gy of the reference). For samples close to the source systematic underestimation could be corrected by accounting for exposure time. Heterogeneity within and between tubes was detected for reference doses as well as for DCA doses estimates., Conclusions: The participants were able to successfully estimate the doses and to provide important information on the exposure scenarios under conditions closely resembling a real-life situation.- Published
- 2021
- Full Text
- View/download PDF
13. Radiation therapy combined with intracerebral convection-enhanced delivery of cisplatin or carboplatin for treatment of the F98 rat glioma.
- Author
-
Elleaume H, Barth RF, Rousseau J, Bobyk L, Balosso J, Yang W, Huo T, and Nakkula R
- Subjects
- Animals, Brain Neoplasms pathology, Carboplatin administration & dosage, Cisplatin administration & dosage, Convection, Glioma pathology, Infusions, Intralesional, Rats, Antineoplastic Combined Chemotherapy Protocols pharmacology, Brain Neoplasms therapy, Chemoradiotherapy methods, Drug Delivery Systems, Glioma therapy
- Abstract
Background: The purpose of this review is to summarize our own experimental studies carried out over a 13-year period of time using the F98 rat glioma as model for high grade gliomas. We evaluated a binary chemo-radiotherapeutic modality that combines either cisplatin (CDDP) or carboplatin, administered intracerebrally (i.c.) by means of convection-enhanced delivery (CED) or osmotic pumps, in combination with either synchrotron or conventional X-irradiation., Methods: F98 glioma cells were implanted stereotactically into the brains of syngeneic Fischer rats. Approximately 14 days later, either CDDP or carboplatin was administered i.c. by CED, followed 24 h later by radiotherapy using either a synchrotron or, subsequently, megavoltage linear accelerators (LINAC)., Results: CDDP was administered at a dose of 3 µg in 5 µL, followed 24 h later with an irradiation dose of 15 Gy or carboplatin at a dose of 20 µg in 10 µL, followed 24 h later with 3 fractions of 8 Gy each, at the source at the European Synchrotron Radiation Facility (ESRF). This resulted in a median survival time (MeST) > 180 days with 33% long term survivors (LTS) for CDDP and a MeST > 60 days with 8 to 22% LTS, for carboplatin. Subsequently it became apparent that comparable survival data could be obtained with megavoltage X-irradiation using a LINAC source. The best survival data were obtained with a dose of 72 µg of carboplatin administered by means of Alzet® osmotic pumps over 7 days. This resulted in a MeST of > 180 days, with 55% LTS. Histopathologic examination of all the brains of the surviving rats revealed no residual tumor cells or evidence of significant radiation related effects., Conclusions: The results obtained using this combination therapy has, to the best of our knowledge, yielded the most promising survival data ever reported using the F98 glioma model.
- Published
- 2020
- Full Text
- View/download PDF
14. Long-term exposure of A549 cells to titanium dioxide nanoparticles induces DNA damage and sensitizes cells towards genotoxic agents.
- Author
-
Armand L, Tarantini A, Beal D, Biola-Clier M, Bobyk L, Sorieul S, Pernet-Gallay K, Marie-Desvergne C, Lynch I, Herlin-Boime N, and Carriere M
- Subjects
- A549 Cells, Alveolar Epithelial Cells metabolism, Alveolar Epithelial Cells pathology, Cell Culture Techniques, Cell Survival drug effects, Comet Assay, Dose-Response Relationship, Drug, Humans, Micronucleus Tests, Microscopy, Electron, Transmission, Mutagens chemistry, Nanoparticles chemistry, Particle Size, Reactive Oxygen Species metabolism, Time Factors, Titanium chemistry, Alveolar Epithelial Cells drug effects, DNA Damage, Mutagens toxicity, Nanoparticles toxicity, Titanium toxicity
- Abstract
Titanium dioxide nanoparticles (TiO2-NPs) are one of the most produced NPs in the world. Their toxicity has been studied for a decade using acute exposure scenarios, i.e. high exposure concentrations and short exposure times. In the present study, we evaluated their genotoxic impact using long-term and low concentration exposure conditions. A549 alveolar epithelial cells were continuously exposed to 1-50 μg/mL TiO2-NPs, 86% anatase/14% rutile, 24 ± 6 nm average primary diameter, for up to two months. Their cytotoxicity, oxidative potential and intracellular accumulation were evaluated using MTT assay and reactive oxygen species measurement, transmission electron microscopy observation, micro-particle-induced X-ray emission and inductively-coupled plasma mass spectroscopy. Genotoxic impact was assessed using alkaline and Fpg-modified comet assay, immunostaining of 53BP1 foci and the cytokinesis-blocked micronucleus assay. Finally, we evaluated the impact of a subsequent exposure of these cells to the alkylating agent methyl methanesulfonate. We demonstrate that long-term exposure to TiO2-NPs does not affect cell viability but causes DNA damage, particularly oxidative damage to DNA and increased 53BP1 foci counts, correlated with increased intracellular accumulation of NPs. In addition, exposure over 2 months causes cellular responses suggestive of adaptation, characterized by decreased proliferation rate and stabilization of TiO2-NP intracellular accumulation, as well as sensitization to MMS. Taken together, these data underline the genotoxic impact and sensitization effect of long-term exposure of lung alveolar epithelial cells to low levels of TiO2-NPs.
- Published
- 2016
- Full Text
- View/download PDF
15. Molecular responses of alveolar epithelial A549 cells to chronic exposure to titanium dioxide nanoparticles: A proteomic view.
- Author
-
Armand L, Biola-Clier M, Bobyk L, Collin-Faure V, Diemer H, Strub JM, Cianferani S, Van Dorsselaer A, Herlin-Boime N, Rabilloud T, and Carriere M
- Subjects
- Cell Line, Tumor, Humans, Titanium chemistry, Epithelial Cells metabolism, Nanoparticles, Proteome metabolism, Proteomics, Pulmonary Alveoli metabolism, Respiratory Mucosa metabolism, Titanium pharmacology
- Abstract
Although the biological effects of titanium dioxide nanoparticles (TiO2-NPs) have been studied for more than two decades, the mechanisms governing their toxicity are still unclear. We applied 2D-gel proteomics analysis on A549 epithelial alveolar cells chronically exposed for 2months to 2.5 or 50μg/mL of deeply characterized TiO2-NPs, in order to obtain comprehensive molecular responses that may reflect functional outcomes. We show that exposure to TiO2-NPs impacts the abundance of 30 protein species, corresponding to 22 gene products. These proteins are involved in glucose metabolism, trafficking, gene expression, mitochondrial function, proteasome activity and DNA damage response. Besides, our results suggest that p53 pathway is activated, slowing down cell cycle progression and reducing cell proliferation rate. Moreover, we report increased content of chaperones-related proteins, which suggests homeostasis re-establishment. Finally, our results highlight that chronic exposure to TiO2-NPs affects the same cellular functions as acute exposure to TiO2-NPs, although lower exposure concentrations and longer exposure times induce more intense cellular response., Biological Significance: Our results make possible the identification of new mechanisms that explain TiO2-NP toxicity upon long-term, in vitro exposure of A549 cells. It is the first article describing -omics results obtained with this experimental strategy. We show that this long-term exposure modifies the cellular content of proteins involved in functions including mitochondrial activity, intra- and extracellular trafficking, proteasome activity, glucose metabolism, and gene expression. Moreover we observe modification of content of proteins that activate the p53 pathway, which suggest the induction of a DNA damage response. Technically, our results show that exposure of A549 cells to a high concentration of TiO2-NPs leads to the identification of modulations of the same functional categories than exposure to low, more realistic concentrations. Still the intensity differs between these two exposure scenarios. We also show that chronic exposure to TiO2-NPs induces the modulation of cellular functions that have already been reported in the literature as being impacted in acute exposure scenarios. This proves that the exposure protocol in in vitro experiments related to nanoparticle toxicology might be cautiously chosen since inappropriate scenario may lead to inappropriate and/or incomplete conclusions., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
16. DNA-polyamine cross-links generated upon one electron oxidation of DNA.
- Author
-
Silerme S, Bobyk L, Taverna-Porro M, Cuier C, Saint-Pierre C, and Ravanat JL
- Subjects
- Animals, Cattle, Chromatography, High Pressure Liquid, DNA isolation & purification, Molecular Structure, Oxidation-Reduction, Tandem Mass Spectrometry, Cross-Linking Reagents chemistry, DNA chemistry, Electrons, Polyamines chemistry
- Abstract
The possibility to induce the formation of covalent cross-links between polyamines and guanine following one electron oxidation of double stranded DNA has been evaluated. For such a purpose, a strategy has been developed to chemically synthesize the polyamine-C8-guanine adducts, and efforts have been made to characterize them. Then, an analytical method, based on HPLC separation coupled through electrospray ionization to tandem mass spectrometry, has been setup for their detection and quantification. Using such a sensitive approach, we have demonstrated that polyamine-C8-guanine adducts could be produced with significant yields in double stranded DNA following a one-electron oxidation reaction induced by photosensitization. These adducts, involving either putrescine, spermine, or spermidine, are generated by the nucleophilic addition of primary amino groups of polyamines onto the C8 position of the guanine radical cation. Our data demonstrate that such a nucleophilic addition of polyamines is much more efficient than the addition of a water molecule that leads to 8-oxo-7,8-dihydroguanine formation.
- Published
- 2014
- Full Text
- View/download PDF
17. Photoactivation of gold nanoparticles for glioma treatment.
- Author
-
Bobyk L, Edouard M, Deman P, Vautrin M, Pernet-Gallay K, Delaroche J, Adam JF, Estève F, Ravanat JL, and Elleaume H
- Subjects
- Animals, Brain pathology, Brain radiation effects, Brain ultrastructure, Brain Neoplasms pathology, Brain Neoplasms radiotherapy, Cell Line, Tumor, Cell Survival radiation effects, Drug Administration Routes, Glioma diagnostic imaging, Glioma pathology, Gold toxicity, Kaplan-Meier Estimate, Male, Metal Nanoparticles toxicity, Neostriatum drug effects, Neostriatum pathology, Radiography, Rats, Rats, Inbred F344, Subcellular Fractions metabolism, Subcellular Fractions radiation effects, X-Rays, Brain Neoplasms diagnostic imaging, Glioma radiotherapy, Gold radiation effects, Light, Metal Nanoparticles radiation effects
- Abstract
Radiosensitization efficacy of gold nanoparticles (AuNPs) with low energy radiations (88 keV) was evaluated in vitro and in vivo on rats bearing glioma. In vitro, a significant dose-enhancement factor was measured by clonogenic assays after irradiation with synchrotron radiation of F98 glioma cells in presence of AuNPs (1.9 and 15 nm in diameter). In vivo, 1.9 nm nanoparticles were found to be toxic following intracerebral delivery in rats bearing glioma, whether no toxicity was observed using 15 nm nanoparticles at the same concentration (50 mg/mL). The therapeutic efficacy of gold photoactivation was determined by irradiating the animals after intracerebral infusion of AuNPs. Survival of rats that had received the combination of treatments (AuNPs: 50 mg/mL, 15 Gy) was significantly increased in comparison with the survival of rats that had received irradiation alone. In conclusion, this experimental approach is promising and further studies are foreseen for improving its therapeutic efficacy., From the Clinical Editor: These investigators report that gold nanoparticles of the correct size can be used to enhance the effects of irradiation in the context of a glioma model. Since many of the glioma varieties are currently incurable, this or similar approaches may find their way to clinical trials in the near future., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
18. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
- Author
-
Boudousq V, Bobyk L, Busson M, Garambois V, Jarlier M, Charalambatou P, Pèlegrin A, Paillas S, Chouin N, Quenet F, Maquaire P, Torgue J, Navarro-Teulon I, and Pouget JP
- Subjects
- Animals, Cell Line, Tumor, Female, Humans, Mice, Mice, Nude, Receptor, ErbB-2 metabolism, Receptors, Cell Surface metabolism, Antibodies, Monoclonal immunology, Lead Radioisotopes, Peritoneal Neoplasms diagnosis, Radioimmunotherapy methods, Receptor, ErbB-2 immunology, Receptors, Cell Surface immunology
- Abstract
Background and Purpose: We assessed the contribution of antibody internalization in the efficacy and toxicity of intraperitoneal α-radioimmunotherapy (RIT) of small volume carcinomatosis using (212)Pb-labeled monoclonal antibodies (mAbs) that target HER2 (internalizing) or CEA (non-internalizing) receptors., Materials and Methods: Athymic nude mice bearing 2-3 mm intraperitoneal tumor xenografts were intraperitoneally injected with similar activities (370, 740 and 1480 kBq; 37 MBq/mg) of (212)Pb-labeled 35A7 (anti-CEA), trastuzumab (anti-HER2) or PX (non-specific) mAbs, or with equivalent amounts of unlabeled mAbs, or with NaCl. Tumor volume was monitored by bioluminescence and survival was reported. Hematologic toxicity and body weight were assessed. Biodistribution of (212)Pb-labeled mAbs and absorbed dose-effect relationships using MIRD formalism were established., Results: Transient hematological toxicity, as revealed by white blood cells and platelets numbering, was reported in mice treated with the highest activities of (212)Pb-labeled mAbs. The median survival (MS) was significantly higher in mice injected with 1.48 MBq of (212)Pb-35A7 (non-internalizing mAbs) (MS = 94 days) than in animals treated with the same activity of (212)Pb-PX mAbs or with NaCl (MS = 18 days). MS was even not reached after 130 days when follow-up was discontinued in mice treated with 1.48 MBq of (212)Pb-trastuzumab. The later efficacy was unexpected since final absorbed dose resulting from injection of 1.48 MBq, was higher for (212)Pb-35A7 (35.5 Gy) than for (212)Pb-trastuzumab (27.6 Gy). These results also highlight the lack of absorbed dose-effect relationship when mean absorbed dose was calculated using MIRD formalism and the requirement to perform small-scale dosimetry., Conclusions: These data indicate that it might be an advantage of using internalizing anti-HER2 compared with non-internalizing anti-CEA (212)Pb-labeled mAbs in the therapy of small volume xenograft tumors. They support clinical investigations of (212)Pb-mAbs RIT as an adjuvant treatment after cytoreductive surgery in patients with peritoneal carcinomatosis.
- Published
- 2013
- Full Text
- View/download PDF
19. Monochromatic minibeams radiotherapy: from healthy tissue-sparing effect studies toward first experimental glioma bearing rats therapy.
- Author
-
Deman P, Vautrin M, Edouard M, Stupar V, Bobyk L, Farion R, Elleaume H, Rémy C, Barbier EL, Estève F, and Adam JF
- Subjects
- Animals, Blood Volume radiation effects, Brain Neoplasms blood supply, Brain Neoplasms mortality, Brain Neoplasms pathology, Cranial Irradiation instrumentation, Feasibility Studies, Glioma blood supply, Glioma mortality, Glioma pathology, Magnetic Resonance Imaging, Male, Models, Animal, Organ Sparing Treatments instrumentation, Organs at Risk, Radiotherapy methods, Radiotherapy Dosage, Rats, Rats, Inbred F344, Survival Analysis, Synchrotrons instrumentation, Brain Neoplasms radiotherapy, Cranial Irradiation methods, Glioma radiotherapy, Organ Sparing Treatments methods
- Abstract
Purpose: The purpose of this study was to evaluate high-dose single fraction delivered with monochromatic X-rays minibeams for the radiotherapy of primary brain tumors in rats., Methods and Materials: Two groups of healthy rats were irradiated with one anteroposterior minibeam incidence (four minibeams, 123 Gy prescribed dose at 1 cm depth in the brain) or two interleaved incidences (54 Gy prescribed dose in a 5 × 5 × 4.8 mm(3) volume centered in the right hemisphere), respectively. Magnetic resonance imaging (MRI) follow-up was performed over 1 year. T2-weighted (T2w) images, apparent diffusion coefficient (ADC), and blood vessel permeability maps were acquired. F98 tumor bearing rats were also irradiated with interleaved minibeams to achieve a homogeneous dose of 54 Gy delivered to an 8 × 8 × 7.8 mm(3) volume centered on the tumor. Anatomic and functional MRI follow-up was performed every 10 days after irradiation. T2w images, ADC, and perfusion maps were acquired., Results: All healthy rats were euthanized 1 year after irradiation without any clinical alteration visible by simple examination. T2w and ADC measurements remain stable for the single incidence irradiation group. Localized Gd-DOTA permeability, however, was observed 9 months after irradiation for the interleaved incidences group. The survival time of irradiated glioma bearing rats was significantly longer than that of untreated animals (49 ± 12.5 days versus 23.3 ± 2 days, p < 0.001). The tumoral cerebral blood flow and blood volume tend to decrease after irradiation., Conclusions: This study demonstrates the sparing effect of minibeams on healthy tissue. The increased life span achieved for irradiated glioma bearing rats was similar to the one obtained with other radiotherapy techniques. This experimental tumor therapy study shows the feasibility of using X-ray minibeams with high doses in brain tumor radiotherapy., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.